Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma

NCT05535244 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05535244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 17, 2022
Completion date
February 26, 2027
Enrollment
90 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma